Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia

Scott T. Miller, Kathy Rey, Jin He, Jonathan Flanagan, Billie J. Fish, Zora R. Rogers, Winfred C. Wang, Russell E. Ware

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) confirmed safety and efficacy of hydroxyurea therapy for infants with sickle cell anemia. Treatment was associated with reduction in rates of pain, acute chest syndrome, hospitalizations, and blood transfusions; improved hematologic values; and, perhaps, preservation of organ function. During the study, a 2-year-old ingested at one time an entire 35-day supply of hydroxyurea (612mg/kg body weight). Despite a serum level of 7,756μM 4hours post-ingestion, the only toxicity was transient mild myelosuppression. With wider usage of hydroxyurea anticipated, conservative management of future overdoses seems reasonable (ClinicalTrials.gov NCT00006400).

Original languageEnglish (US)
Pages (from-to)170-172
Number of pages3
JournalPediatric Blood and Cancer
Volume59
Issue number1
DOIs
StatePublished - Jul 15 2012

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Acute Chest Syndrome
Organ Preservation
Phase III Clinical Trials
Blood Transfusion
Hospitalization
Eating
Body Weight
Pediatrics
Safety
Pain
Therapeutics
Serum

Keywords

  • BABY HUG
  • Drug toxicity
  • Hydroxycarbamide
  • Infant
  • Poisoning

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. / Miller, Scott T.; Rey, Kathy; He, Jin; Flanagan, Jonathan; Fish, Billie J.; Rogers, Zora R.; Wang, Winfred C.; Ware, Russell E.

In: Pediatric Blood and Cancer, Vol. 59, No. 1, 15.07.2012, p. 170-172.

Research output: Contribution to journalArticle

Miller, ST, Rey, K, He, J, Flanagan, J, Fish, BJ, Rogers, ZR, Wang, WC & Ware, RE 2012, 'Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia', Pediatric Blood and Cancer, vol. 59, no. 1, pp. 170-172. https://doi.org/10.1002/pbc.23244
Miller, Scott T. ; Rey, Kathy ; He, Jin ; Flanagan, Jonathan ; Fish, Billie J. ; Rogers, Zora R. ; Wang, Winfred C. ; Ware, Russell E. / Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. In: Pediatric Blood and Cancer. 2012 ; Vol. 59, No. 1. pp. 170-172.
@article{63d30abac56947489755d64f272080a6,
title = "Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia",
abstract = "The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) confirmed safety and efficacy of hydroxyurea therapy for infants with sickle cell anemia. Treatment was associated with reduction in rates of pain, acute chest syndrome, hospitalizations, and blood transfusions; improved hematologic values; and, perhaps, preservation of organ function. During the study, a 2-year-old ingested at one time an entire 35-day supply of hydroxyurea (612mg/kg body weight). Despite a serum level of 7,756μM 4hours post-ingestion, the only toxicity was transient mild myelosuppression. With wider usage of hydroxyurea anticipated, conservative management of future overdoses seems reasonable (ClinicalTrials.gov NCT00006400).",
keywords = "BABY HUG, Drug toxicity, Hydroxycarbamide, Infant, Poisoning",
author = "Miller, {Scott T.} and Kathy Rey and Jin He and Jonathan Flanagan and Fish, {Billie J.} and Rogers, {Zora R.} and Wang, {Winfred C.} and Ware, {Russell E.}",
year = "2012",
month = "7",
day = "15",
doi = "10.1002/pbc.23244",
language = "English (US)",
volume = "59",
pages = "170--172",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia

AU - Miller, Scott T.

AU - Rey, Kathy

AU - He, Jin

AU - Flanagan, Jonathan

AU - Fish, Billie J.

AU - Rogers, Zora R.

AU - Wang, Winfred C.

AU - Ware, Russell E.

PY - 2012/7/15

Y1 - 2012/7/15

N2 - The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) confirmed safety and efficacy of hydroxyurea therapy for infants with sickle cell anemia. Treatment was associated with reduction in rates of pain, acute chest syndrome, hospitalizations, and blood transfusions; improved hematologic values; and, perhaps, preservation of organ function. During the study, a 2-year-old ingested at one time an entire 35-day supply of hydroxyurea (612mg/kg body weight). Despite a serum level of 7,756μM 4hours post-ingestion, the only toxicity was transient mild myelosuppression. With wider usage of hydroxyurea anticipated, conservative management of future overdoses seems reasonable (ClinicalTrials.gov NCT00006400).

AB - The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) confirmed safety and efficacy of hydroxyurea therapy for infants with sickle cell anemia. Treatment was associated with reduction in rates of pain, acute chest syndrome, hospitalizations, and blood transfusions; improved hematologic values; and, perhaps, preservation of organ function. During the study, a 2-year-old ingested at one time an entire 35-day supply of hydroxyurea (612mg/kg body weight). Despite a serum level of 7,756μM 4hours post-ingestion, the only toxicity was transient mild myelosuppression. With wider usage of hydroxyurea anticipated, conservative management of future overdoses seems reasonable (ClinicalTrials.gov NCT00006400).

KW - BABY HUG

KW - Drug toxicity

KW - Hydroxycarbamide

KW - Infant

KW - Poisoning

UR - http://www.scopus.com/inward/record.url?scp=84861217720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861217720&partnerID=8YFLogxK

U2 - 10.1002/pbc.23244

DO - 10.1002/pbc.23244

M3 - Article

VL - 59

SP - 170

EP - 172

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -